PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Qianquan Ma; Qianquan Ma; Qianquan Ma; Wenyong Long; Changsheng Xing; Chongming Jiang; Jun Su; Helen Y. Wang; Qing Liu; Rong-Fu Wang; Rong-Fu Wang; Rong-Fu Wang; Rong-Fu Wang

doi:10.3389/fonc.2020.573318

Frontiers in Oncology (Oct 2020)

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Qianquan Ma,
Qianquan Ma,
Qianquan Ma,
Wenyong Long,
Changsheng Xing,
Chongming Jiang,
Jun Su,
Helen Y. Wang,
Qing Liu,
Rong-Fu Wang,
Rong-Fu Wang,
Rong-Fu Wang,
Rong-Fu Wang

Affiliations

Qianquan Ma: Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China
Qianquan Ma: Department of Neurosurgery in the Third Hospital of Peking University, Peking University, Beijing, China
Qianquan Ma: Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, United States
Wenyong Long: Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China
Changsheng Xing: Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Chongming Jiang: Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, United States
Jun Su: Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China
Helen Y. Wang: Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Qing Liu: Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China
Rong-Fu Wang: Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, United States
Rong-Fu Wang: Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Rong-Fu Wang: Department of Pediatrics, Children’s Hospital of Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Rong-Fu Wang: Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

DOI: https://doi.org/10.3389/fonc.2020.573318
Journal volume & issue: Vol. 10

Abstract

Read online

Glioblastoma (GBM) stem cells are resistant to cancer therapy, and therefore responsible for tumor progression and recurrence after conventional therapy. However, the molecular mechanisms driving the maintenance of stemness and dedifferentiation are poorly understood. In this study, we identified plant homeodomain finger-containing protein 20 (PHF20) as a crucial epigenetic regulator for sustaining the stem cell-like phenotype of GBM. It is highly expressed in GBM and tightly associated with high levels of aggressiveness of tumors and potential poor prognosis in GBM patients. Knockout of PHF20 inhibits GBM cell proliferation, as well as its invasiveness and stem cell-like traits. Mechanistically, PHF20 interacts with WDR5 and binds to the promoter regions of WISP1 for its expression. Subsequently, WISP1 and BGN act in concert to regulate the degradation of β-Catenin. Our findings have identified PHF20 as a key driver of GBM malignant behaviors, and provided a potential target for developing prognosis and therapy.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords